Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPical sirolimus in linGUal microkystic lymphatic malformation
2024-515955-39-01Phase 2Completed
- Sponsor
- CHRU Tours
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sirolimus in lingual microcystic lymphatic malformation (MLM), sponsored by CHRU Tours. Primary endpoint: Change in global severity of LMLM by blinded-expert PGA score at 12 weeks. Started Aug 2024; status: completed.
02
Drugs
sirolimus
03
Conditions
lingual microcystic lymphatic malformation (MLM)
Beyond the preview
Go deeper on 2024-515955-39-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515955-39-01.